Additional Information:
Export Date: 26 August 2021 Correspondence Address: Griffiths, G.O.; Southampton Clinical Trials Unit, Southampton, United Kingdom; email: G.O.Griffiths@soton.ac.uk Funding details: AstraZeneca Funding details: Merck Funding details: Roche Funding details: Wellcome Trust, WT Funding details: University Hospital Southampton NHS Foundation Trust Funding details: UCB Funding details: UK Research and Innovation, UKRI, EP/R024804/1 Funding details: Gilead UK and Ireland Corporate Contributions Funding details: Medical Research Council, MRC Funding details: Engineering and Physical Sciences Research Council, EPSRC Funding details: National Institute for Health Research, NIHR Funding details: Cancer Research UK, CRUK Funding details: University of Southampton Funding details: University of Liverpool, UoL Funding details: Chienkuo Technology University, CTU Funding details: UCLH Biomedical Research Centre, NIHR BRC, BRC-1215-20014, MC_UU_00002/14, NIHR300576 Funding text 1: We acknowledge Cancer Research UK (CRUK) who, during the COVID-19 crisis, allowed its staff at Southampton CTU to work with the National Institute for Health Research (NIHR) community (e.g. Southampton CTU, Liverpool CRF & Southampton Biomedical Research Centre) to develop this phase I/II trial platform. We acknowledge the University Hospital Southampton NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, University of Southampton and the University of Liverpool who supported and collaborated in the development of AGILE. We acknowledge the Global Health Trials Unit within the Liverpool School of Tropical Medicine who are leading in developing AGILE international trials with our international partners in South Africa and Uganda. We also acknowledge The Wellcome Trust and the Medical Research Council (MRC)/UK Research and Innovation (UKRI) for core funding this project. Funding text 2: We acknowledge Cancer Research UK (CRUK) who, during the COVID-19 crisis, allowed its staff at Southampton CTU to work with the National Institute for Health Research (NIHR) community (e.g. Southampton CTU, Liverpool CRF & Southampton Biomedical Research Centre) to develop this phase I/II trial platform. We acknowledge the University Hospital Southampton NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, University of Southampton and the University of Liverpool who supported and collaborated in the development of AGILE. We acknowledge the Global Health Trials Unit within the Liverpool School of Tropical Medicine who are leading in developing AGILE international trials with our international partners in South Africa and Uganda. We also acknowledge The Wellcome Trust and the Medical Research Council (MRC)/UK Research and Innovation (UKRI) for core funding this project. Funding text 3: The development of the AGILE master protocol, electronic data capture system, randomisation and eConsent was funded using Cancer Research UK (CRUK) core funding and National Institute for Health Research (NIHR) CTU support funding at the Southampton Clinical Trials Unit. NIHR funding at the Royal Liverpool and Broadgreen Clinical Research Facility and staff at the University of Liverpool and Lancaster also supported the development of the master protocol and its associated documentation (e.g. participant information sheets, case report forms). Funding for each CST protocol is a mixture of core funding and investigator-initiated research grants from pharmaceutical companies supplying the candidate. Funding for CST3 was provided by Unitaid and preclinical evaluation of nitazoxanide was supported by UKRI using funding repositioned from EP/R024804/1 as part of the UK emergency response to COVID-19. We have core funding from The Wellcome Trust and the Medical Research Council (MRC)/UK Research and Innovation (UKRI). TJ was supported by the NIHR, Cambridge Biomedical Research Centre (BRC-1215-20014) and by UK Medical Research Council (grant number: MC_UU_00002/14). PM was supported by NIHR Advanced Fellowship (NIHR300576).The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Funding text 4: AO is a Director of Tandem Nano Ltd and co-inventor of patents relating to drug delivery. Also unrelated, AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck. MP receives research funding from various organisations including the MRC and NIHR. He has also received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis), a PhD studentship jointly funded by EPSRC and Astra Zeneca and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT ( www.ardat.org ). None of these of funding sources have been used for the current paper. References: Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Tan, W., A novel coronavirus from patients with pneumonia in China, 2019 (2020) N Engl J Med., 382 (8), pp. 727-733; Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Cao, B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (2020) Lancet., 395 (10223), pp. 497-506; Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Zhang, L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study (2020) Lancet., 395 (10223), pp. 507-513; Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Peng, Z., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China (2020) Jama., 323 (11), pp. 1061-1069; Treatments and Vaccines for Covid 19: Authorised Medicines 2021, , https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19; Wise, J., Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows (2021) Bmj., 372, p. n433; Kim, P.S., Read, S.W., Fauci, A.S., Therapy for early COVID-19: a critical need (2020) Jama., 324 (21), pp. 2149-2150; Burki, T., Understanding variants of SARS-CoV-2 (2021) The Lancet., 397 (10273), p. 462; A minimal common outcome measure set for COVID-19 clinical research (2020) Lancet Infect Dis, 20 (8), pp. e192-e1e7; Agostini, M.L., Pruijssers, A.J., Chappell, J.D., Gribble, J., Lu, X., Andres, E.L., Small-molecule antiviral β-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance (2019) J Virol, 93 (24), pp. e01348-19. , https://doi.org/10.1128/JVI.01348-19; Toots, M., Yoon, J.J., Cox, R.M., Hart, M., Sticher, Z.M., Makhsous, N., Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia (2019) Sci Transl Med, 11 (515), p. eaax5866. , (,):,., https://doi.org/10.1126/scitranslmed.aax5866; Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebocontrolled, phase 2b/3 trial (2014) Lancet Infect Dis, 14 (7), pp. 609-618. , https://doi.org/10.1016/S1473-3099(14)70717-0; Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R.K.R., Curley, P., Neary, M., Owen, A., Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics (2020) Clin Pharmacol Ther., 108 (4), pp. 775-790; Rajoli, R.K.R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis (2021) Br J Clin Pharmacol, 87 (4), pp. 2078-2088. , (,):, -,., https://doi.org/10.1111/bcp.14619; Pinto, D., Park, Y.J., Beltramello, M., Walls, A.C., Tortorici, M.A., Bianchi, S., Jaconi, S., Corti, D., Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody (2020) Nature., 583 (7815), pp. 290-295; Bournazos, S., Corti, D., Virgin, H.W., Ravetch, J.V., Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection (2020) Nature., 588 (7838), pp. 485-490